Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

Jean‐Robert Delpéro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0000-1332; OpenAlex author ID A5081081344. Sources: OpenAlex.

Their work

Papers
38 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
130
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 6 papers · 2016: 3 papers · 2017: 6 papers · 2018: 3 papers · 2019: 4 papers · 2020: 5 papers · 2021: 5 papers

Papers 38

  1. Acute Pancreatitis as the Initial Presentation of Pancreatic Adenocarcinoma does not Impact Short- and Long-term Outcomes of Curative Intent Surgery: A Study o… Co-author DOI 10.1007/s00268-021-06205-1↗
  2. A Novel Pancreatic Fistula Risk Score Including Preoperative Radiation Therapy in Pancreatic Cancer Patients. Co-author DOI 10.1007/s11605-020-04600-y↗
  3. Does pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancreatic adenocarcinoma affect postoperative morbidity … Co-author DOI 10.1016/j.hpb.2021.04.003↗
  4. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  5. Prospective Evaluation of Resection Margins Using Standardized Specimen Protocol Analysis among Patients with Distal Cholangiocarcinoma and Pancreatic Ductal A… Co-author DOI 10.3390/jcm10153247↗
  6. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Co-author DOI 10.1016/j.ejso.2020.02.037↗
  7. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.12.001↗
  8. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. Co-author DOI 10.1186/s12885-020-6690-1↗
  9. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? Co-author DOI 10.1186/s12893-020-00835-3↗
  10. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. Co-author DOI 10.3389/fonc.2020.00040↗
  11. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Co-author DOI 10.1016/j.ctrv.2019.05.007↗
  12. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement. Co-author DOI 10.1016/j.jviscsurg.2018.06.014↗
  13. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-019-1637-1↗
  14. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  15. Severe postoperative complications decrease overall and disease free survival in pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Last author DOI 10.1016/j.ejso.2018.03.024↗
  16. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Last author DOI 10.1016/j.suronc.2018.07.014↗
  17. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Co-author DOI 10.1038/s41467-018-04383-6↗
  18. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  19. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  20. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment?… Co-author DOI 10.1016/j.ejso.2017.06.011↗
  21. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. Co-author DOI 10.1186/s12916-017-0936-z↗
  22. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  23. Venous Resection in Pancreatic Ductal Adenocarcinoma: Impact of Surgical Experience on Early Postoperative Courses. Last author DOI 10.21873/anticanres.11811↗
  24. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  25. Prognostic value of PDL1 expression in pancreatic cancer. Co-author DOI 10.18632/oncotarget.11685↗
  26. Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. Co-author PMID 27107061↗
  27. Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.jamcollsurg.2015.03.058↗
  28. Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: Time for a Randomized Controlled Trial? Results of an All-inclusive National Observati… Last author DOI 10.1097/sla.0000000000001479↗
  29. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0667↗
  30. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Associati… Co-author DOI 10.1245/s10434-014-4304-3↗
  31. Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence. Co-author DOI 10.18632/oncoscience.172↗
  32. [Management of localized, locally advanced and metastatic pancreatic adenocarcinoma]. Co-author PMID 26016202↗
  33. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  34. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. Co-author DOI 10.1111/hpb.12061↗
  35. [Pancreatic adenocarcinoma: what treatment?]. First author PMID 25638875↗
  36. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … Co-author DOI 10.1093/annonc/mds135↗
  37. Genome profiling of pancreatic adenocarcinoma. Co-author DOI 10.1002/gcc.20870↗
  38. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Co-author DOI 10.1186/1471-2407-11-346↗

Closest collaborators

The 25 strongest of 130 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Olivıer Turrini · 27 shared papers, 2011–2021 · strength 2.09
  2. Marine Gilabert · 15 shared papers, 2012–2021 · strength 1.18
  3. Ugo Marchèse · 9 shared papers, 2019–2021 · strength 1.03
  4. Flora Poizat · 12 shared papers, 2016–2021 · strength 1.02
  5. Jonathan Garnier · 10 shared papers, 2016–2021 · strength 0.99
  6. Alain Sauvanet Sauvanet · 11 shared papers, 2014–2021 · strength 0.88
  7. Marc F. Giovannini · 11 shared papers, 2011–2020 · strength 0.71
  8. Jean‐Luc Raoul · 9 shared papers, 2011–2018 · strength 0.48
  9. François Paye · 7 shared papers, 2014–2021 · strength 0.44
  10. Laurence Moureau-Zabotto · 5 shared papers, 2012–2020 · strength 0.43
  11. L. Chiche · 5 shared papers, 2015–2021 · strength 0.36
  12. Philippe Bachellier · 6 shared papers, 2011–2021 · strength 0.34
  13. Pauline Duconseil · 5 shared papers, 2016–2019 · strength 0.29
  14. Mehdi Ouaïssi · 5 shared papers, 2015–2017 · strength 0.26
  15. Juan Iovanna · 6 shared papers, 2011–2018 · strength 0.26
  16. António Sá Cunha · 4 shared papers, 2015–2019 · strength 0.25
  17. Nelson Dusetti · 5 shared papers, 2015–2018 · strength 0.24
  18. Mustapha Adham · 3 shared papers, 2015–2021 · strength 0.23
  19. Christophe Laurent · 2 shared papers, 2019–2021 · strength 0.20
  20. Daniel Birnbaum · 4 shared papers, 2011–2017 · strength 0.19
  21. Émilie Mamessier · 4 shared papers, 2011–2017 · strength 0.19
  22. David Jérémie Birnbaum · 4 shared papers, 2011–2017 · strength 0.19
  23. Véronique Secq · 4 shared papers, 2016–2018 · strength 0.19
  24. Odile Gayet · 4 shared papers, 2016–2018 · strength 0.19
  25. Benjamin Bian · 4 shared papers, 2016–2018 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.